1. Home
  2. KRG vs GRFS Comparison

KRG vs GRFS Comparison

Compare KRG & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kite Realty Group Trust

KRG

Kite Realty Group Trust

HOLD

Current Price

$24.32

Market Cap

5.2B

Sector

Real Estate

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$9.53

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRG
GRFS
Founded
1971
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
6.2B
IPO Year
2004
2006

Fundamental Metrics

Financial Performance
Metric
KRG
GRFS
Price
$24.32
$9.53
Analyst Decision
Buy
Hold
Analyst Count
9
2
Target Price
$25.33
$10.15
AVG Volume (30 Days)
2.0M
452.1K
Earning Date
02-10-2026
07-28-2022
Dividend Yield
4.81%
1.50%
EPS Growth
N/A
N/A
EPS
0.64
0.64
Revenue
$856,786,000.00
$8,821,017,248.00
Revenue This Year
$1.91
$5.36
Revenue Next Year
N/A
$5.15
P/E Ratio
$37.97
$18.71
Revenue Growth
3.78
7.31
52 Week Low
$18.52
$6.19
52 Week High
$24.69
$11.14

Technical Indicators

Market Signals
Indicator
KRG
GRFS
Relative Strength Index (RSI) 66.22 65.21
Support Level $23.36 $9.17
Resistance Level $24.20 $9.46
Average True Range (ATR) 0.32 0.19
MACD 0.00 0.04
Stochastic Oscillator 89.67 100.00

Price Performance

Historical Comparison
KRG
GRFS

About KRG Kite Realty Group Trust

Kite Realty Group Trust specializes in owning, operating, acquiring, developing, and redeveloping high-quality open-air shopping centers and mixed-use assets. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: